SAN FRANCISCO -- November 12, 2026 -- Thryv Therapeutics closed a $30 million Series B financing led by InClin, Inc., and Chairman and CEO Paul Truex will present the company's SGK1 inhibitor pipeline at the UBS Global Biopharma Conference in London. Existing investors also took part in the round, according to the company.
The fireside chat is scheduled for Tuesday, November 17, 2026, at 3:20 pm GMT (10:20 am ET), on the second day of the November 16-17 conference. Thryv will also hold one-on-one investor meetings. The talk comes before the first efficacy data from the company's lead candidate, THRV-1268, which the company expects in early 2027.
Thryv has completed enrollment in the first efficacy cohort of Wave II, a Phase 2/3 study (NCT07277582) of THRV-1268 in patients with Long QT Syndrome Type 2 and Type 3. Both the Wave II readout and the opening of enrollment in the company's second trial fall in early 2027.
That second trial is ASPIRE-HF, a Phase 2a study of THRV-1268 in patients with heart failure with reduced ejection fraction and QTc prolongation. Wave II tests the drug in inherited rhythm disorders, while ASPIRE-HF extends it to a heart failure population. The company describes SGK1 as sitting at the intersection of electrical and structural heart disease.
The company did not disclose how it will allocate the $30 million between the two trials.
Thryv has set up clinical operations in Australia ahead of the early 2027 enrollment start for ASPIRE-HF.